Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Becton, Dickinson (BDX) Beats On Q4 Earnings And Revenues

ByZacks Investment Research
Published 11/04/2019, 10:36 PM
Updated 07/09/2023, 06:31 AM
Earnings of Other MedTech Majors at a Glance
Some better-ranked companies, which posted solid results this earnings season, are Edwards Lifesciences (EW), Thermo Fisher Scientific Inc. (TMO) and ResMed Inc. (RMD), each carrying a Zacks Rank #2 (Buy) You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which surpassed the consensus estimate by 2.1%. Revenues of $6.27 billion outpaced the consensus estimate by 1.3%.
ResMed reported fiscal first-quarter 2020 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Becton, Dickinson and Company (BDX), also known as BD, reported fourth-quarter fiscal 2019 earnings per share (EPS) of $3.31, which beat the Zacks Consensus Estimate by a penny. The bottom line also improved 13% on a year-over-year basis and rose 12.3% at constant currency (cc).
The Zacks Rank #4 (Sell) company raked in revenues of $4.58 billion, surpassing the Zacks Consensus Estimate of $4.57 billion. The reported figure increased 4.1% from the year-ago quarter. At cc, revenues rose 6.2%.
FY19 at a Glance
On a full-year basis, BD’s revenues increased 8.2% to $17.29 billion, beating the Zacks Consensus Estimate of $17.27 billion. Adjusted EPS was $11.68, up 6.1%. The metric was in line with the Zacks Consensus Estimate.
BD reports through three major segments — BD Medical, BD Life Sciences and BD Interventional.
BD Medical sales were $9.06 billion (52.4% of net sales), BD Life Sciences sales totaled $4.30 billion (24.9%) and BD Interventional sales were $3.93 billion (21.9%).

Becton, Dickinson and Company (NYSE:BDX) , also known as BD, reported fourth-quarter fiscal 2019 earnings per share (EPS) of $3.31, which beat the Zacks Consensus Estimate by a penny. The bottom line also improved 13% on a year-over-year basis and rose 12.3% at constant currency (cc).

The Zacks Rank #4 (Sell) company raked in revenues of $4.58 billion, surpassing the Zacks Consensus Estimate of $4.57 billion. The reported figure increased 4.1% from the year-ago quarter. At cc, revenues rose 6.2%.
FY19 at a Glance
On a full-year basis, BD’s revenues increased 8.2% to $17.29 billion, beating the Zacks Consensus Estimate of $17.27 billion. Adjusted EPS was $11.68, up 6.1%. The metric was in line with the Zacks Consensus Estimate.
BD reports through three major segments — BD Medical, BD Life Sciences and BD Interventional.
BD Medical sales were $9.06 billion (52.4% of net sales), BD Life Sciences sales totaled $4.30 billion (24.9%) and BD Interventional sales were $3.93 billion (21.9%).

Becton, Dickinson and Company Price, Consensus and EPS Surprise

Becton, Dickinson and Company price-consensus-eps-surprise-chart | Becton, Dickinson and Company Quote

Segment Details
BD Medical
In the quarter under review, the company reported worldwide revenues of $2.44 billion, up 3.9% from the year-ago quarter and 5.3% at cc. Per management, the segment's results were driven by performance in the Medication Management Solutions, Medication Delivery Solutions and Pharmaceutical Systems units.
BD Life Sciences
Worldwide revenues in the segment totaled $1.13 billion, up 2.3% year over year and 6.9% at cc. Per management, the upside was driven by solid performance in the Diagnostic Systems and Biosciences units.
BD Interventional
This segment generated worldwide revenues of $1.01 billion, up 6.9% from the year-ago quarter. At cc, revenues grew 7.7% on strong performance by the Urology and Critical Care and Surgery sub-units.
Geographic Results
US
In the fiscal fourth quarter, revenues in the United States improved 4.6% to $2.56 billion. Revenues grew 4.9% at cc. Per management, growth in the United States was driven by good performance by the BD Medical, BD Life Sciences and the Surgery and Urology and Critical Care units within the BD Interventional segment.
International
Revenues outside the United States grossed $2.02 billion, up 3.5% from the year-ago quarter. At cc, the segment grew 7.9%. Per management, international revenue growth in the fourth quarter was strong in APAC and EMEA.
Margin Analysis
In the quarter, gross profit amounted to $2.27 billion, up 8.3% from the prior-year quarter tally. Gross margin was 49.4%, up 190 bps from the prior-year quarter.
Operating income in the quarter grossed $111 million, down significantly from the year-ago quarter’s figure of $576 million. As a percentage of revenues, operating margin in the quarter was 2.4%, significantly down from year-ago quarter’s 13.1%.
Adjusted operating income amounted to $902 million, up 26.2% from the year-ago figure.
Guidance
The company expects fiscal 2020 revenues to increase 4-4.5% year over year and 5-5.5% at cc. The Zacks Consensus Estimate is pegged at $18.13 billion.
Adjusted EPS is expected between $12.50 and $12.65, indicating growth of 7-8.5% from fiscal 2019. At cc, growth is expected between 9.5% and 11%. The Zacks Consensus Estimate for the same stands at $12.92, higher than the guided range.
Wrapping Up
BD exited the fiscal fourth quarter on a strong note. Solid performance by the core BD Medical and Interventional segments instills optimism in the stock. Domestic revenues increased year over year in the quarter under review, driven by segmental strength. Growth in Europe and APAC is another positive. Expansion in gross margin is also encouraging. BD has issued a solid guidance for fiscal 2020.
Meanwhile, a drop in operating margin raises concern. Management expects unfavorable foreign currency to partially mar BD’s bottom line in fiscal 2020. Competition in the MedTech space is stiff.
Earnings of Other MedTech Majors at a Glance
Some better-ranked companies, which posted solid results this earnings season, are Edwards Lifesciences (NYSE:EW) , Thermo Fisher Scientific Inc. (NYSE:TMO) and ResMed Inc. (NYSE:RMD) , each carrying a Zacks Rank #2 (Buy) You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Edwards Lifesciences delivered third-quarter 2019 adjusted EPS of $1.41, outpacing the Zacks Consensus Estimate by 15.6%. Net sales of $1.09 billion surpassed the Zacks Consensus Estimate by 5.5%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, which surpassed the consensus estimate by 2.1%. Revenues of $6.27 billion outpaced the consensus estimate by 1.3%.
ResMed reported fiscal first-quarter 2020 adjusted EPS of 93 cents, which beat the Zacks Consensus Estimate of 87 cents by 6.9%. Revenues were $681.1 million, surpassing the Zacks Consensus Estimate by 3.6%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.


Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report

Edwards Lifesciences Corporation (EW): Free Stock Analysis Report

ResMed Inc. (RMD): Free Stock Analysis Report

Becton, Dickinson and Company (BDX): Free Stock Analysis Report

Original post
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.